Share
15,455 Posts.
lightbulb Created with Sketch. 5536
clock Created with Sketch. 17/07/23
10:08
Share
Originally posted by theplew
↑
I agree.Unmet need for small patient population. I have also noticed that an adult and chronic GVHD trial has been added to the pipeline. I’m tipping that will be announced as part of the approval in a couple of weeks. It works - Real World Evidence Used in Japan for GVHD since 2016 40% market share and growing. Takeda licensed to use rem-l for Crohns complex perianal fistulas - Alofisel since 2017 Alofisel is approved in the European Union/European Economic Area, Israel, Switzerland and the United Kingdom for the treatment of complex perianal fistulas in adult patients Takeda scaled up due to high demand of Alofisel. Invested 36M to build new manufacturing facility in Ireland to supply Crohn’s therapy to patients in Europe, the US and Canada It works, it’s safe, it’s time. And to think this is just the entrée.
Expand
Great summary @theplew 470,708 shares bought at the opening bell @ $1.40 ..... huge start to the morning ... oh and thanks for the laughs this morning from some .... don't you just love those that claim "I have always been right about this company" when they 'actually' haven't - nothing like a bit of self praise for the ego I guess .... LMAO
(20min delay)